SEC Form 4 · accession 0002143491-26-000004
Kiniksa Pharmaceuticals International, plc · KNSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dhiraj H Malkani
Officer — CHIEF STRATEGY OFFICER
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 4:42 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001730430
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share OptionF1 | $62.88 | Jul 1, 2026 | A | 82,600 | A | — | Jun 30, 2036 | Class A Ordinary Share | 82,600 | 0 | D |
| Restricted Share UnitF2,F3 | — | Jul 1, 2026 | A | 14,000 | A | — | — | Class A Ordinary Share | 14,000 | 0 | D |
| Performance Share OptionF4,F5 | $62.88 | Jul 1, 2026 | A | 2,119 | A | — | Jun 30, 2036 | Class A Ordinary Share | 2,119 | 0 | D |
| Performance Share OptionF4,F6 | $62.88 | Jul 1, 2026 | A | 2,188 | A | — | Jun 30, 2036 | Class A Ordinary Share | 2,188 | 0 | D |
| Performance Share UnitF4,F7,F8 | — | Jul 1, 2026 | A | 1,245 | A | — | — | Class A Ordinary Share | 1,245 | 0 | D |
| Performance Share UnitF4,F7,F9 | — | Jul 1, 2026 | A | 1,307 | A | — | — | Class A Ordinary Share | 1,307 | 0 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is July 1, 2026.
- F2Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- F3The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, July 1, 2026.
- F4The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.
- F5The Performance Share Options (PSO) shall vest and become exercisable, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
- F6The PSOs shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
- F7Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance
- F8The PSUs shall vest, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
- F9The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.